Five Prime Therapeutics (NASDAQ:FPRX) was downgraded by investment analysts at ValuEngine from a “sell” rating to a “strong sell” rating in a note issued to investors on Friday.

A number of other brokerages have also recently commented on FPRX. Zacks Investment Research upgraded Five Prime Therapeutics from a “sell” rating to a “buy” rating and set a $49.00 price target on the stock in a research report on Monday, October 16th. Royal Bank of Canada raised their price target on Five Prime Therapeutics from $41.00 to $50.00 and gave the stock an “outperform” rating in a research report on Monday, November 6th. BMO Capital Markets raised their price target on Five Prime Therapeutics from $71.00 to $75.00 and gave the stock an “outperform” rating in a research report on Tuesday, November 7th. Finally, BidaskClub cut Five Prime Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, December 9th. One research analyst has rated the stock with a sell rating, two have assigned a hold rating and six have given a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $64.00.

Five Prime Therapeutics (NASDAQ FPRX) opened at $19.73 on Friday. The firm has a market capitalization of $570.79, a price-to-earnings ratio of -3.89 and a beta of 3.90. Five Prime Therapeutics has a 12-month low of $19.41 and a 12-month high of $49.30.

Five Prime Therapeutics (NASDAQ:FPRX) last posted its quarterly earnings data on Monday, November 6th. The biotechnology company reported ($1.54) earnings per share for the quarter, missing the consensus estimate of ($1.35) by ($0.19). The firm had revenue of $8.33 million for the quarter, compared to the consensus estimate of $16.16 million. Five Prime Therapeutics had a negative return on equity of 41.57% and a negative net margin of 408.42%. The firm’s quarterly revenue was up 24.7% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.72) EPS. equities analysts expect that Five Prime Therapeutics will post -5.56 earnings per share for the current year.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Oppenheimer & Co. Inc. bought a new position in shares of Five Prime Therapeutics in the third quarter worth $223,000. Legal & General Group Plc increased its position in shares of Five Prime Therapeutics by 3.1% in the second quarter. Legal & General Group Plc now owns 9,455 shares of the biotechnology company’s stock worth $288,000 after purchasing an additional 287 shares during the period. Virtu KCG Holdings LLC bought a new position in shares of Five Prime Therapeutics in the second quarter worth $331,000. Dupont Capital Management Corp acquired a new stake in Five Prime Therapeutics in the third quarter valued at about $341,000. Finally, Tudor Investment Corp ET AL boosted its stake in Five Prime Therapeutics by 49.4% in the second quarter. Tudor Investment Corp ET AL now owns 11,999 shares of the biotechnology company’s stock valued at $361,000 after buying an additional 3,966 shares in the last quarter. Institutional investors own 83.74% of the company’s stock.

WARNING: “Five Prime Therapeutics (FPRX) Downgraded by ValuEngine” was first reported by Watch List News and is owned by of Watch List News. If you are accessing this report on another site, it was illegally stolen and reposted in violation of United States and international copyright and trademark legislation. The legal version of this report can be viewed at https://www.watchlistnews.com/five-prime-therapeutics-fprx-downgraded-by-valuengine/1838202.html.

About Five Prime Therapeutics

Five Prime Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing protein therapeutics. The Company’s product candidates include Cabiralizumab (FPA008), which is an antibody that inhibits colony stimulating factor-1 receptor, that it is studying in clinical trials as a monotherapy in pigmented villonodular synovitis, and in multiple cancers in combination with programmed-death 1 immune checkpoint inhibitor, Opdivo; FPA144, which is an antibody that inhibits fibroblast growth factor receptor 2b, that it is initially developing to treat patients with gastric (stomach) cancer and is in a Phase I clinical trial, and FP-1039, which is a fusion protein that traps and neutralizes cancer-promoting fibroblast growth factors, involved in cancer cell proliferation and new blood vessel formation and is in Phase Ib clinical development to treat patients with malignant pleural mesothelioma.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Five Prime Therapeutics (NASDAQ:FPRX)

Receive News & Ratings for Five Prime Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Five Prime Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.